Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Ad5-CD/TKrep; Ad5-yCD/mutTKSR39rep-ADP; Ad5-yCD/mutTKSR39rep-hIL12; Radiation-sensitising gene therapy - NewGenPharm/Henry Ford Health System; Theragene

Latest Information Update: 20 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henry Ford Health System
  • Developer Henry Ford Health System; NewGenPharm
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Astrocytoma
  • No development reported Prostate cancer

Most Recent Events

  • 29 Nov 2022 Phase-I clinical trials in Astrocytoma (Late-stage disease, Recurrent) in USA (Intratumoural) (NCT05686798)
  • 31 Mar 2021 Hengry Ford Health System filed has patent pending for methods, composition involved in Ad5-yCD/mutTK(SR39)rep-ADP in USA by March 2021
  • 17 Mar 2021 Phase-II clinical trials in Pancreatic cancer (Late-stage disease, Adjunctive treatment) in South Korea (Parenteral) (NCT04739046)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top